Topics

Articles

Model N positions itself for coming revisions in pharma trade practices

Acquisition of daVIZta brings more analytics expertise

$21.4-billion acquisition realigns research and manufacturing sourcing

Ex-AmerisourceBergen, -Cardinal and -inVentiv Health execs join team

By working with the sales force, incentive plan design can boost a product launch

Will restricting use of rebates in federal programs carry over to commercial insurance?

Senate and House committees begin the legislative process for addressing drug pricing

Annual analysis predicts 3-6% CAGR through 2023, a lower rate than 2014-2018

Even as the science behind the new therapies is getting established, payers are preparing for their extraordinary cost

Spending on drug promotion rose—but not at the rate of pharma sales growth